Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05175352 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05175352 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 16 participants.
The verdict
NCT05175352, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
Interventions
- DRUG Cendakimab
- DRUG CYP substrates
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-06-07 |
| Est. Completion | 2024-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05175352
The ClinicalTrials.gov registry entry for NCT05175352 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cendakimab is the first listed.
NCT05175352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05175352 about?
NCT05175352 is a clinical study titled "A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab". The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
What is the current status of trial NCT05175352?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2022-06-07. Estimated completion is 2024-10-11.
What interventions are being tested in trial NCT05175352?
The interventions under investigation include: Cendakimab (DRUG), CYP substrates (DRUG).
Who is sponsoring clinical trial NCT05175352?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.